Combination treatment for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This study tests a new drug combination for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have an advanced solid tumor that has grown or spread despite treatment.
- You are able to care for yourself (ECOG 0 or 1).
- You have at least one tumor that can be measured.
- You have not had certain immunotherapies (like CTLA-4 or CD28 inhibitors) before.
- You do not have active brain metastases or other cancers in the last 5 years.
- You have adequate organ function and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs: peginterferon α-2b (an immune-boosting drug) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). They hope the combo might work better for people with advanced solid tumors that haven't responded to other treatments.
This trial tests a new combination treatment called HS-20089 for people with advanced solid tumors. The goal is to see if it is safe and how well it works against cancer that has not responded to other treatments.
This trial tests a new combination of drugs for advanced solid tumors. It may help if your cancer has not responded to other treatments, and the goal is to see how safe and effective this new approach is.
This study tests a combination treatment for people with advanced solid tumors that have not responded to standard therapies. It uses a type of radiation therapy (PRaG) together with another treatment, and is specifically looking at people who have a low level of lymphocytes in their blood, which may affect how well the treatment works.
This trial tests two new study drugs (SCTB41 and SCTB39-1) given together, sometimes with standard treatment, to see if they are safe and effective against advanced solid tumors. If you join, you will receive these drugs and be monitored for how well they fight the cancer.
This trial tests a new combination of drugs (FC084CSA plus tislelizumab) for people with advanced solid tumors, especially lung cancer that has gotten worse after prior immunotherapy and chemotherapy. It may be an option if you've tried standard treatments and they no longer work.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.